IDEAYA Biosciences (IDYA) Other Non-Current Assets (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Other Non-Current Assets of $1.3 million for Q1 2026, up 26.21% sequentially from $1.0 million in Q4 2025, and up 59.13% YoY from $805000.0 in Q1 2025.
IDEAYA Biosciences (IDYA) Other Non-Current Assets (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Other Non-Current Assets for 9 years, with the latest figure at $1.3 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 59.13% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 59.13% YoY) and the FY2025 annual result came in at $1.0 million, up 26.09% from the prior year.
- Other Non-Current Assets rose to $1.3 million in Q1 2026 per IDYA's latest filing, from $1.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.3 million in Q1 2026 and troughed at $106000.0 in Q1 2022.
- A 5-year average of $636823.5 and a median of $757000.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets plunged 63.57% in 2022, then surged 614.15% in 2023.
- Over 5 years, Other Non-Current Assets stood at $106000.0 in 2022, then soared by 614.15% to $757000.0 in 2023, then climbed by 6.34% to $805000.0 in 2024, then rose by 26.09% to $1.0 million in 2025, then rose by 26.21% to $1.3 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.3 million, $1.0 million, and $805000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | 1.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.28 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | 1.02 Mn |
| Sep 30, 2025 | 805,000.00 |
| Jun 30, 2025 | 805,000.00 |
| Mar 31, 2025 | 805,000.00 |
| Dec 31, 2024 | 805,000.00 |
| Sep 30, 2024 | 911,000.00 |
| Jun 30, 2024 | 911,000.00 |
| Mar 31, 2024 | 757,000.00 |
| Dec 31, 2023 | 757,000.00 |
| Sep 30, 2023 | 722,000.00 |
| Jun 30, 2023 | 722,000.00 |
| Mar 31, 2023 | 106,000.00 |
| Dec 31, 2022 | 106,000.00 |
| Sep 30, 2022 | 106,000.00 |
| Jun 30, 2022 | 106,000.00 |
| Mar 31, 2022 | 106,000.00 |
| Dec 31, 2021 | 291,000.00 |
| Sep 30, 2021 | 217,000.00 |